JP2018528237A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528237A5
JP2018528237A5 JP2018515566A JP2018515566A JP2018528237A5 JP 2018528237 A5 JP2018528237 A5 JP 2018528237A5 JP 2018515566 A JP2018515566 A JP 2018515566A JP 2018515566 A JP2018515566 A JP 2018515566A JP 2018528237 A5 JP2018528237 A5 JP 2018528237A5
Authority
JP
Japan
Prior art keywords
sequence
seq
epitope
protein
cell epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018515566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528237A (ja
JP7090335B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/072690 external-priority patent/WO2017050966A1/en
Publication of JP2018528237A publication Critical patent/JP2018528237A/ja
Publication of JP2018528237A5 publication Critical patent/JP2018528237A5/ja
Application granted granted Critical
Publication of JP7090335B2 publication Critical patent/JP7090335B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018515566A 2015-09-25 2016-09-23 治療剤に対する免疫応答を除去するための改善された方法及び化合物 Expired - Fee Related JP7090335B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15186845.2 2015-09-25
EP15186845 2015-09-25
PCT/EP2016/072690 WO2017050966A1 (en) 2015-09-25 2016-09-23 Improved methods and compounds for eliminating immune responses to therapeutic agents

Publications (3)

Publication Number Publication Date
JP2018528237A JP2018528237A (ja) 2018-09-27
JP2018528237A5 true JP2018528237A5 (https=) 2019-11-07
JP7090335B2 JP7090335B2 (ja) 2022-06-24

Family

ID=54251983

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018515566A Expired - Fee Related JP7090335B2 (ja) 2015-09-25 2016-09-23 治療剤に対する免疫応答を除去するための改善された方法及び化合物

Country Status (8)

Country Link
US (2) US11787849B2 (https=)
EP (2) EP3939606A3 (https=)
JP (1) JP7090335B2 (https=)
CN (1) CN108289941B (https=)
AU (2) AU2016328582B2 (https=)
CA (1) CA2995771A1 (https=)
ES (1) ES2874077T3 (https=)
WO (1) WO2017050966A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
ES2545886T3 (es) 2008-02-14 2015-09-16 Life Sciences Research Partners Vzw Inmunoterapia dirigida a patógenos intracelulares
EP2247306B1 (en) 2008-02-14 2018-04-18 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
ES2924027T3 (es) 2010-11-25 2022-10-04 Imcyse Sa Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
JP7090335B2 (ja) 2015-09-25 2022-06-24 イムサイス エスエー 治療剤に対する免疫応答を除去するための改善された方法及び化合物
AU2017252192C1 (en) 2016-04-19 2023-06-08 Imcyse Sa Novel immunogenic CD1d binding peptides
EP3592765A1 (en) 2017-03-09 2020-01-15 ImCyse SA Peptides and methods for the treatment of diabetes
US20230113747A1 (en) * 2019-05-16 2023-04-13 Imcyse Sa Immunogenic peptides with an oxidoreductase motif comprising a modified cysteine
WO2021148683A2 (en) * 2020-05-06 2021-07-29 Imcyse Sa Peptides and methods for the treatment of multiple sclerosis
CN115867567A (zh) * 2020-05-06 2023-03-28 易姆赛斯股份公司 具有新氧化还原酶基序的免疫原性肽
WO2021224397A1 (en) * 2020-05-06 2021-11-11 Imcyse Sa Immunogenic peptides with extended oxidoreductase motifs
CN113621030B (zh) * 2020-07-14 2023-05-26 上海科技大学 一种诱导蛋白质降解的多肽及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
AU579148B2 (en) 1984-03-09 1988-11-17 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell and b cell determinants
US4886782A (en) 1987-02-26 1989-12-12 The United States Of America As Represented By The Department Of Health And Human Services Malarial immunogen
US5433948A (en) 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
ATE238065T1 (de) 1990-09-27 2003-05-15 Tripep Ab Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
ATE444360T1 (de) 1991-10-16 2009-10-15 Merck Patent Gmbh T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe)
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5589582A (en) 1992-10-27 1996-12-31 Biotransplant, Inc. Polynucleotides en coding porcine cytokines
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5824315A (en) 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
AU1124499A (en) 1997-10-28 1999-05-17 Maxygen, Inc. Human papillomavirus vectors
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US20030152581A1 (en) 1998-07-30 2003-08-14 Jean-Marie Saint-Remy Compound and method for the prevention and/or the treatment of allergy
AR020102A1 (es) 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
CA2350911A1 (en) 1998-11-16 2000-05-25 Board Of Regents, The University Of Texas System Hiv-specific t-cell induction
GB0006437D0 (en) 2000-03-17 2000-05-10 Leuven Res & Dev Vzw Compounds for the modulation of allergen sensitivity by antigens sharing T cell epitopes with allergens
EP2258835A1 (en) * 2000-04-28 2010-12-08 Novozymes A/S Lipolytic enzyme variant
AU2001272491A1 (en) 2000-06-26 2002-01-08 Smithkline Beecham Biologicals (S.A.) Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
EP1409650B1 (en) 2001-05-30 2006-04-12 Fondazione Telethon Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof
JP4537060B2 (ja) 2001-10-03 2010-09-01 ユニリーバー・ナームローゼ・ベンノートシヤープ 治療剤および他剤の送達のための炭水化物結合領域含有融合タンパク質、およびそれらを含む組成物
AU2003215395A1 (en) 2002-02-21 2003-09-09 Apovia, Inc. STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
US20100183652A1 (en) 2002-02-21 2010-07-22 Mark Page STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
TW200413406A (en) 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
DK2261249T3 (en) 2002-09-12 2015-02-16 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
JP2004147649A (ja) 2002-10-11 2004-05-27 Kumamoto Technology & Industry Foundation 頭頚部癌の抗原
US20070054262A1 (en) 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
US7651855B2 (en) 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
GB0324265D0 (en) 2003-10-16 2003-11-19 Medical Res Council Peptide
WO2005042575A2 (en) * 2003-10-30 2005-05-12 Pharmexa A/S Method for down-regulation of vegf
JP2008044848A (ja) 2004-11-30 2008-02-28 Univ Kurume Hla−a24拘束性腫瘍抗原ペプチド
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
FR2898275B1 (fr) 2006-03-10 2012-12-14 Genethon Cellules t regulatrices cd4+cd25+specifiques pour la greffe de cellules hematopoietiques et la tolerance immunitaire
WO2007135684A2 (en) 2006-05-22 2007-11-29 Hadasit Medical Research Services & Development Limited Method of treatment of anti-cd4 autoimmunity
ES2709176T3 (es) * 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
CA2700618A1 (en) 2007-09-27 2009-04-02 The Board Of Trustees Of The University Of Arkansas Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor
ES2545886T3 (es) 2008-02-14 2015-09-16 Life Sciences Research Partners Vzw Inmunoterapia dirigida a patógenos intracelulares
EP2252329B1 (en) 2008-02-14 2015-06-17 Life Sciences Research Partners VZW Elimination of immune responses to viral vectors
EP2247306B1 (en) 2008-02-14 2018-04-18 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
EP2249864B1 (en) 2008-02-14 2016-05-04 Life Sciences Research Partners VZW Strategies to prevent and/or treat immune responses to soluble allofactors
US9248171B2 (en) 2008-02-14 2016-02-02 Imcyse Sa Immunogenic peptides and their use in transplantation
CA2715536C (en) 2008-02-14 2018-01-16 Life Sciences Research Partners Vzw Cd4+ t-cells with cytolytic properties
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
CN103002909B (zh) 2010-03-29 2016-06-29 国家科学研究中心 包含含有至少一个cxxc基序的多肽和异源抗原的药物组合物及其用途
ES2924027T3 (es) 2010-11-25 2022-10-04 Imcyse Sa Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
SG10201609500QA (en) 2012-02-15 2016-12-29 Ecole Polytech Erythrocyte-binding therapeutics
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201315946D0 (en) 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
GB201319160D0 (en) * 2013-10-30 2013-12-11 Imcyse Sa Methods for induction of antigen-specific regulatory t cells
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
JP7090335B2 (ja) 2015-09-25 2022-06-24 イムサイス エスエー 治療剤に対する免疫応答を除去するための改善された方法及び化合物
AU2017252192C1 (en) 2016-04-19 2023-06-08 Imcyse Sa Novel immunogenic CD1d binding peptides

Similar Documents

Publication Publication Date Title
JP2018528237A5 (https=)
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
RU2020113032A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
IL309801A (en) Use of protein domains interacting with the nucleosome to enhance targeted genome modification
JP2017018125A5 (https=)
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
NZ751946A (en) Rna-guided nucleic acid modifying enzymes and methods of use thereof
MX2018009225A (es) Inmunoterapia basada en vectores de distribución personalizados y usos de la misma.
IL259120A (en) Her2-targeted antigen chimeric receptors2
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
JP2013507907A5 (https=)
WO2020047467A3 (en) Cardiac cell reprogramming with myocardin and ascl1
JP2017538401A5 (https=)
JP2016501829A5 (https=)
JP2010506826A5 (https=)
CN103160530B (zh) 一种融合基因及其应用
JP2017514522A5 (https=)
EP3939606A3 (en) Improved methods and compounds for eliminating immune responses to therapeutic agents
RU2017127024A (ru) Герпесвирус с измененным спектром мишеней, содержащий гибридный гликопротеин н
HRP20192262T1 (hr) Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc)
JP2019530441A5 (https=)
JP2015511599A5 (https=)
WO2016130628A8 (en) Griffithsin mutants
EP4353256A3 (en) Induction of cross-reactive cellular response against rhinovirus antigens
RU2012147590A (ru) Пептиды cdca5 и содержащие их вакцины